Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis

Summary

This purpose of this study was to demonstrate the efficacy of secukinumab versus placebo on nail psoriasis and to assess long-term efficacy, safety and tolerability of secukinumab.

Timeline

Start

2013-06-20

Primary completion

2017-01-03

Completion

2017-01-03

Outcome

Met primary endpoint

registry AIN457 150 mg vs Placebo; p <0.0001; Mean Difference (Net) -26.7 (95% CI -39.1 to -14.3) NCT01807520 ↗

registry AIN457 300 mg vs Placebo; p <0.0001; Mean Difference (Net) -34.4 (95% CI -45.2 to -23.5) NCT01807520 ↗

release “Similarly, in the TRANSFIGURE study in patients with significant nail psoriasis, Cosentyx (300 mg) was superior to placebo at Week 16” novartis.com ↗

release “Cosentyx (secukinumab) met the primary endpoints of superiority compared to placebo in patients with difficult-to-treat psoriasis of the nails, palms and soles” novartis.com ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Secukinumab	Monoclonal antibody	150 mg	Subcutaneous
Subject	Secukinumab	Monoclonal antibody	300 mg	Subcutaneous

Indications

No indication recorded.